US Pharmaceutical Market Size and Forecast (2020-2030)
US Pharmaceutical Market Size and Forecast (2020 – 2030), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Vaccines, Biologics & Biosimilars, and Small Molecules)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Pharmaceutical is a broad segment that consolidates a group of chemicals classified based on their pharmacological effect and therapeutic use. For instance, alkaloids were the first pure pharmaceuticals derived from plants; they include quinine, nicotine, cocaine, atropine, and morphine. Similarly, some drugs are made of animal origin, which includes glandular extracts containing hormones. These pharmaceutical products diagnose, treat, and prevent chronic diseases such as cancer, diabetes, and genetic disorders.
Market Opportunity
Increasing Adoption of AI-Based Tools for Drug Discovery
Artificial intelligence (AI) is emerging as an important tool in the healthcare sector, as it helps understand the action mechanism of drugs. The use of AI tools has already been proven to accelerate the process of discovering new candidate therapeutics; the process that earlier used to take years to complete can now be accomplished within months using AI. In addition to reducing the timelines of drug discovery, AI helps enhance the agility of the research process, increase the accuracy of predictions on drug safety and efficacy, and boost the speed and precision of discovery and preclinical testing, thereby providing a competitive edge to R&D strategies.
Many pharmaceutical companies are collaborating with AI companies to harness the benefits of AI in drug discovery. For instance, in 2019, Pfizer partnered with Concreto HealthAI to advance its work in precision oncology using AI and real-world data. The company believes that AI tools have tremendous potential in developing and using drugs to improve patient outcomes. Further, in 2022, Pfizer extended its partnership with CytoReason to leverage its AI technology for improving drug candidate discovery and drug development processes. Similarly, in 2019, Janssen collaborated with a French startup Iktos Pharmaceuticals to develop an AI-powered drug design system. Janssen’s new drug design system will enhance the process of discovering new medications by accelerating the identification of molecules. Additionally, in January 2020, Bayer partnered with a UK-based AI-driven drug discovery company, where Bayer will use the AI drug discovery platform to identify and optimize novel structures as potential drug candidates to treat cardiovascular and oncological diseases. Similarly, GlaxoSmithKline (GSK) collaborated with Insilico Medicine, a Baltimore-based AI-driven company, to explore the AI capability of Insilico for easing the process of identification of novel biological targets.
Thus, the growing adoption of AI-based tools for drug discovery is likely to trigger the growth of the US pharmaceutical market during the forecast period.
Segmental Analysis
Product-Based Insights
The US pharmaceutical market, by product, is segmented into vaccines, biologicals & biosimilars, and small molecules. The small molecules segment is further bifurcated into generic and branded. The small molecules segment held the largest market share in 2022. The biologicals & biosimilars segment is expected to register the highest CAGR during the forecast period. In the US pharmaceutical market growth, biosimilars treat patients with cancers, kidney diseases, diabetes, and other autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Biologics are the most expensive medicines in the US pharmaceutical market outlook, costing tens of thousands of dollars yearly per patient. Biosimilars are expected to be priced 15–30% lower than their reference product. In 2020 alone, biosimilars saved US$ 7.9 billion, with savings expected to grow significantly in the next few years as more biosimilars enter the market. According to Cardinal Health, it is expected that biosimilars are expected to reduce the US drug expenditure by US$ 133 billion by 2025. The recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve the quality of life among millions of patients while saving billions of dollars for healthcare systems per year. They have come up as potent and cost-effective options for treating many diseases—including chronic skin conditions such as psoriasis; bowel diseases such as Crohn’s disease, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis. During 2017–2018, the National Health Service (NHS) saved US$ 401.10 million by switching from 10 expensive medicines to better-value and equally effective alternatives such as biologics, with an expectation of even more savings in the future. The potential savings from using biosimilars can also be used to fund other new treatments. With the high prevalence of chronic diseases, the demand for biosimilars in treating life-threatening illnesses has surged rapidly over the last five years. Such a factor has assisted the growth of the US pharmaceutical market in the recent past and is expected to follow a similar trend during the forecast period.
Country Analysis
In recent years, pharmaceutical sales revenues in the US pharmaceutical market outlook have accounted for nearly half of the global total. Five of the 10 top US pharmaceutical market companies worldwide were from the US in 2021. Pfizer is one of the companies that provides prescription drug revenues worldwide, heavily boosted by its COVID-19 vaccine Comirnaty. AbbVie is another US pharmaceutical market participant that has made a great impression worldwide, with the pharmaceutical segment generating a record US$ 55 billion in 2021, driven especially by its longstanding top-seller brand Humira. Despite the influence of several emerging countries, the US has captured a dominant share of the pharmaceutical market globally. The US pharmaceutical market is home to a few major pharma companies worldwide. Most advanced US pharmaceutical market products are easily accessible to American consumers, albeit at a cost.
The US pharmaceutical market accounts for about 45% of the global pharmaceutical market and 22% of global production. The US pharmaceuticals output and sales remained robust in 2022, driven by the global vaccination rollout and suppressed demand for essential and non-essential medical treatments. The US pharmaceutical market has made great strides over the past few decades due to a greater focus on research and development (R&D). Pharma companies spend over 21% of their revenues on R&D, and this sizeable investment is wasted if a medication does not receive regulatory approval. The R&D expenditure of the US pharmaceutical market totaled some US$ 102 billion in 2021. This figure will likely increase significantly in the coming years due to the costs of developing effective and safe COVID-19 treatments and vaccines.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
Pharmaceutical is a broad segment that consolidates a group of chemicals classified based on their pharmacological effect and therapeutic use. For instance, alkaloids were the first pure pharmaceuticals derived from plants; they include quinine, nicotine, cocaine, atropine, and morphine. Similarly, some drugs are made of animal origin, which includes glandular extracts containing hormones. Drugs or medicines from animal origins are biological, biosimilar, and vaccines. These pharmaceutical products diagnose, treat, and prevent chronic diseases such as cancer, diabetes, and genetic disorders.
Key External Drivers
Advantages Offered by Continuous Manufacturing Process
Batch manufacturing has been the most common and traditionally used mode of manufacturing in the pharmaceutical industry for more than a century. However, with the rising demand for biologics and increasing trend of contract manufacturing, flexible manufacturing alternatives such as CM processes are being embraced and gaining importance lately.
In December 2022, as part of launching a suite of R&D analytical solutions, the US Pharmacopeia (USP) opened the USP Advanced Manufacturing Technology Lab in Richmond, Virginia. The analytical lab services will support the efforts of drug manufacturers striving to adopt advanced manufacturing technologies, including pharmaceutical continuous manufacturing (PCM), as one way to support increased geographic diversity in pharmaceutical manufacturing and support medicines supply chain resilience.
Continuous pharmaceutical manufacturing involves the process of extracting the drug from its base ingredients to final product without being halted during the production activity. According to the Food and Drug Administration (FDA), the pharmaceutical manufacturing industry ends up wasting up to US$ 50 billion every year on average and inefficient processes. CM serves to be a potential solution for this problem, as well as provides various other advantages, including more time-efficiency, reduced energy needs, and increased productivity.
Furthermore, the risk of human error is reduced in the continuous process due to a fewer number of people are involved in the manufacturing process. Thus, the advantages offered by CM over batch manufacturing procedure are anticipated to drive the growth of the US pharmaceutical market over the coming years.
Increasing Geriatric Population
Since 2009, the elderly population has increased by 36% (with the addition of 14.4 million) in the US. As per the report 2020 Profile of Older Americans, 54.1 million people in the US were aged 65 and above in 2019, of which 30 million were women and 24.1 million were men. According to the 2020 population statistics by the US Census Bureau, the geriatric population reached 55.8 million, i.e., 16.8% of the national population; nearly 1 in 6 people in the country were aged 65 and above in 2020. Further, 16% of the total population that was aged 65 and above in 2019 is expected to increase to 21.6% by 2040. Such a factor is expected to aid the US pharmaceutical market trends at present.
With growing age, people are more likely to experience several health conditions simultaneously. Aging is characterized by the development of many complex health issues, commonly known as geriatric syndromes. Common conditions diagnosed in older age are cataracts and refractive errors, hearing loss, back and neck pain, chronic obstructive pulmonary disease, osteoarthritis, depression, dementia, and diabetes, among others. Senior citizens regularly require healthcare services and medications, owing to which the pharmaceutical industry witnesses a notable demand. Thus, increasing life expectancy contributes to the growth of the US pharmaceutical market.
Product-Based Insights
The US pharmaceutical market, by product, is segmented into vaccines, biologicals & biosimilars, and small molecules. The small molecules segment is further bifurcated into generic and branded. The small molecules segment held the largest market share in 2022. The biologicals & biosimilars segment is expected to register the highest CAGR during the forecast period. In the US pharmaceutical market growth, biosimilars treat patients with cancers, kidney diseases, diabetes, and other autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Biologics are the most expensive medicines in the US pharmaceutical market outlook, costing tens of thousands of dollars yearly per patient. Biosimilars are expected to be priced 15–30% lower than their reference product. In 2020 alone, biosimilars saved US$ 7.9 billion, with savings expected to grow significantly in the next few years as more biosimilars enter the market. According to Cardinal Health, it is expected that biosimilars are expected to reduce the US drug expenditure by US$ 133 billion by 2025. The recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve the quality of life among millions of patients while saving billions of dollars for healthcare systems per year. They have come up as potent and cost-effective options for treating many diseases—including chronic skin conditions such as psoriasis; bowel diseases such as Crohn’s disease, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis. During 2017–2018, the National Health Service (NHS) saved US$ 401.10 million by switching from 10 expensive medicines to better-value and equally effective alternatives such as biologics, with an expectation of even more savings in the future in the US pharmaceutical market. The potential savings from using biosimilars can also be used to fund other new treatments. With the high prevalence of chronic diseases, the demand for biosimilars in treating life-threatening illnesses has surged rapidly over the last five years. Such a factor has assisted the growth of the US pharmaceutical market share in the recent past and is expected to follow a similar trend during the forecast period.
Johnson & Johnson, Merck & Co Inc, Abbott Laboratories, Amgen Inc, Eli Lilly and Company, Bristol-Myers Squibb Company, Bayer AG, Takeda Pharmaceuticals, Zoetis Inc, Moderna Inc, AbbVie Inc, Pfizer Inc, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc are a few of the key companies operating in the US pharmaceutical market. Leading players focus on expanding and diversifying their market presence and clientele, tapping prevailing business opportunities.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the US pharmaceutical market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the global US pharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth country market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction 16
1.1 Scope of the Study. 16
2. Pharmaceutical Market – Key Takeaways 17
3. Research Methodology 21
3.1 Coverage. 22
3.2 Secondary Research. 23
3.3 Primary Research. 24
4. Pharmaceutical Market – Market Landscape 25
4.1 Overview. 25
4.2 PESTLE Analysis. 25
4.2.1 Political Factors. 25
4.2.2 Economic Factors. 25
4.2.3 Social Factors. 26
4.2.4 Technological Factors. 26
4.2.5 Legal Factors. 27
4.2.6 Environmental Factors. 27
4.3 Expert’s Opinion. 28
4.4 Macro-Economic Framework of the U.S. 28
4.5 Import and Export Activities in the U.S. and Italy. 31
4.5.1 Import – Export Analysis. 31
4.5.2 US. 37
4.5.3 Italy. 50
4.6 Magazines, Publications, Universities, and Online Portals. 60
4.7 Events List 65
4.8 Trade Shows List 67
4.9 Useful Contacts -Events and Trade Shows, Associations, and Magazines. 68
4.9.1 Associations – MAIN PHARMACEUTICAL, VACCINE AND CONSUMER PRODUCT TRADE ASSOCIATIONS. 74
4.9.2 Magazines – Trade Magazines, Blogs, Journals, and Publications. 81
4.10 Information Regarding CDMOs. 84
4.10.1 Surplus/Deficit information. 84
4.10.2 Trade Balance. 84
4.10.3 Production and investment Done in the recent Past 85
4.10.4 Initiatives Taken by Pharmaceutical Countries. 86
4.11 Supply Chain Distribution Channel 87
4.12 Suggestions and Opportunities For Italian Companies. 98
4.13 Industry Performance. 99
4.14 Industry Outlook. 100
4.14.1 Market Size and Growth. 100
4.14.2 Research and Development (R&D) 100
4.14.3 Market Dynamics. 100
4.14.4 Regulatory Landscape. 101
4.14.5 Market Access and Pricing. 101
4.14.6 COVID-19 Impact 101
4.14.7 Generics and Biosimilars. 101
4.14.8 Digital Health Integration. 101
4.14.9 Supply Chain Resilience. 102
4.14.10 Workforce and Employment 102
4.14.11 Downward Pressure on Pricing. 102
4.14.12 From Treatment to Prevention and Beyond. 103
4.15 Key External Drivers. 103
4.15.1 Increasing Geriatric Population. 103
4.15.2 Advantages Offered by Continuous Manufacturing Process. 104
4.16 Demand Determinants in Future. 104
4.16.1 Growing Interest of Pharmaceutical Companies to Promote Product Sales through Contract Sales Organizations. 104
4.16.2 Rising Number of Healthcare Start-ups. 105
4.17 Industry Trends in the US Market 106
4.17.1 Increasing Adoption of Continuous Manufacturing in Pharmaceuticals. 106
4.17.2 Growing Adoption of AI-based Tools for Drug Discovery. 106
4.17.3 Growing Adoption of Self-Injecting Parenteral Devices. 106
5. Pharmaceutical Market – Key Market Dynamics 110
5.1 Market Drivers. 110
5.1.1 Rising Workplace-Associated Disorders. 110
5.1.2 Rise in Pharmaceutical Production Capacity. 111
5.1.3 Increased Approvals of Generic Drugs. 112
5.1.4 Escalating R&D Investments in Pharmaceutical Industry. 112
5.2 Market Restraints. 113
5.2.1 High Cost of Drug Development and Marketing Approval 113
5.3 Market Opportunities. 113
5.3.1 Rising Incidences of Chronic Diseases and Infectious Diseases. 113
5.3.2 Emerging Markets for Outsourcing Production Activities. 114
5.4 Future Trends. 115
5.4.1 Increasing Adoption of AI-based Tools for Drug Discovery. 115
5.5 Impact Analysis. 116
6. Pharmaceutical Market – US Analysis 117
6.1 US Pharmaceutical Market Revenue Forecast and Analysis. 117
6.1.1 US: Pharmaceutical Market, by Product, 2019–2030 (US$ Billion) 118
6.1.1.1 US: Pharmaceuticals Market For Product, by Type, 2019–2030 (US$ Billion) 118
6.2 Production mapping. 119
6.2.1 Pharma companies in the US- 119
6.2.2 The impact of COVID-19 on R&D- 119
6.3 Pricing Analysis of Key Products. 119
6.4 Production and Sales Statistics of Pharmaceutical Market in US. 122
6.5 Value Chain Analysis and Vendor’s Ecosystem.. 124
6.6 Go-to-Market Strategies for Companies. 125
6.6.1 Johnson & Johnson. 125
6.6.2 Pfizer Inc. 126
6.6.3 Merck Co & Inc. 126
6.7 Regulatory Scenario in the United States Associated With Pharmaceutical Industry. 127
6.7.1 Agencies, Organizations, Institutes, Centers, and Offices Associated with Pharmaceutical Product Regulation. 128
6.7.2 Regulations to enter and operate within the USA Market 128
6.8 HTS Codes for Drugs in United States. 129
6.8.1 Custom Duties. 131
6.8.2 Link Between HTS Codes and Custom Duties. 131
7. US Branded Small Molecules Market 132
7.1 US: Branded Small Molecules Market Revenue and Forecast to 2030. 132
7.1.1 Overview. 132
7.1.2 US: Branded Small Molecules Market Positioning Analysis. 134
7.1.3 US Branded Small Molecules Market – Revenue and Forecast to 2030 (USD Billion) 135
8. US Generic Small Molecules Market 136
8.1 US: Generic Small Molecules Market Revenue and Forecast to 2030. 136
8.1.1 Overview. 136
8.1.2 US: Generic Small Molecules Market Positioning Analysis: 138
8.1.3 US Generic Small Molecules Market – Revenue and Forecast to 2030 (USD Billion) 139
9. US Biological and Biosimilar Products Market 140
9.1 US: Biological and Biosimilar Products Market Revenue and Forecast to 2030. 140
9.1.1 Overview. 140
9.1.2 US: Biological and Biosimilar Products Market Positioning Analysis: 142
9.1.3 US Biological and Biosimilar Products Market – Revenue and Forecast to 2030 (USD Billion) 143
10. US Vaccines Market 144
10.1 US: Vaccines Market Revenue and Forecast to 2030. 144
10.1.1 Overview. 144
10.1.2 US: Vaccines Market Positioning Analysis: 146
10.1.3 US Vaccines Market – Revenue and Forecast to 2030 (USD Billion) 147
11. Pharmaceutical Market – Industry Landscape 148
11.1 Overview. 148
11.2 Growth Strategies in the Pharmaceutical Market 148
11.3 Inorganic Growth Strategies. 149
11.3.1 Overview. 149
11.4 Organic Growth Strategies. 150
11.4.1 Overview. 150
12. Company Profiles 152
12.1 Moderna Inc. 152
12.1.1 Key Facts. 152
12.1.2 Business Description. 152
12.1.3 Products and Services. 153
12.1.4 Financial Overview. 154
12.1.5 SWOT Analysis. 156
12.1.6 Key Developments. 158
12.2 AbbVie Inc. 159
12.2.1 Key Facts. 159
12.2.2 Business Description. 159
12.2.3 Products and Services. 160
12.2.4 Financial Overview. 161
12.2.5 SWOT Analysis. 164
12.2.6 Key Developments. 168
12.3 Gilead Sciences Inc. 169
12.3.1 Key Facts. 169
12.3.2 Business Description. 169
12.3.3 Products and Services. 170
12.3.4 Financial Overview. 171
12.3.5 SWOT Analysis. 173
12.3.6 Key Developments. 177
12.4 Regeneron Pharmaceuticals Inc. 178
12.4.1 Key Facts. 178
12.4.2 Business Description. 178
12.4.3 Products and Services. 179
12.4.4 Financial Overview. 180
12.4.5 SWOT Analysis. 181
12.4.6 Key Developments. 185
12.5 Merck & Co Inc. 186
12.5.1 Key Facts. 186
12.5.2 Business Description. 186
12.5.3 Products and Services. 187
12.5.4 Financial Overview. 188
12.5.5 SWOT Analysis. 191
12.5.6 Key Developments. 195
12.6 Abbott Laboratories. 196
12.6.1 Key Facts. 196
12.6.2 Business Description. 196
12.6.3 Products and Services. 197
12.6.4 Financial Overview. 199
12.6.5 SWOT Analysis. 202
12.6.6 Key Developments. 206
12.7 Bristol-Myers Squibb Co. 207
12.7.1 Key Facts. 207
12.7.2 Business Description. 207
12.7.3 Products and Services. 208
12.7.4 Financial Overview. 209
12.7.5 SWOT Analysis. 211
12.7.6 Key Developments. 215
12.8 Vertex Pharmaceuticals Inc. 216
12.8.1 Key Facts. 216
12.8.2 Business Description. 216
12.8.3 Products and Services. 217
12.8.4 Financial Overview. 218
12.8.5 SWOT Analysis. 220
12.8.6 Key Developments. 222
12.9 Pfizer Inc. 223
12.9.1 Key Facts. 223
12.9.2 Business Description. 223
12.9.3 Products and Services. 224
12.9.4 Financial Overview. 225
12.9.5 SWOT Analysis. 227
12.9.6 Key Developments. 231
12.10 Eli Lilly and Co. 233
12.10.1 Key Facts. 233
12.10.2 Business Description. 233
12.10.3 Products and Services. 234
12.10.4 Financial Overview. 235
12.10.5 SWOT Analysis. 237
12.10.6 Key Developments. 241
12.11 Bayer AG. 242
12.11.1 Key Facts. 242
12.11.2 Business Description. 242
12.11.3 Products and Services. 243
12.11.4 Financial Overview. 245
12.11.5 SWOT Analysis. 248
12.11.6 Key Developments. 251
12.12 Johnson & Johnson. 252
12.12.1 Key Facts. 252
12.12.2 Business Description. 252
12.12.3 Products and Services. 253
12.12.4 Financial Overview. 256
12.12.5 SWOT Analysis. 258
12.12.6 Key Developments. 262
12.13 Amgen Inc. 264
12.13.1 Key Facts. 264
12.13.2 Business Description. 264
12.13.3 Products and Services. 265
12.13.4 Financial Overview. 266
12.13.5 SWOT Analysis. 268
12.13.6 Key Developments. 272
12.14 Takeda Pharmaceutical Co Ltd. 273
12.14.1 Key Facts. 273
12.14.2 Business Description. 273
12.14.3 Products and Services. 274
12.14.4 Financial Overview. 275
12.14.5 SWOT Analysis. 278
12.14.6 Key Developments. 282
12.15 Zoetis Inc. 283
12.15.1 Key Facts. 283
12.15.2 Business Description. 283
12.15.3 Products and Services. 284
12.15.4 Financial Overview. 285
12.15.5 SWOT Analysis. 287
12.15.6 Key Developments. 290
LIST OF TABLES
Table 1. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 43
Table 2. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 44
Table 3. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 47
Table 4. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 48
Table 5. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 54
Table 6. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 55
Table 7. Italy Export Trade from US- Product: HSC 30 Pharmaceutical products. 58
Table 8. Italy Export Trade to US- Product: HSC 30 Pharmaceutical products. 59
Table 9. List of Magazines, Publications, Universities, and Online Portals. 61
Table 10. List of Events. 65
Table 11. List of Trade Shows. 67
Table 12. Events and Trade Shows. 68
Table 13. Counts of total nonfatal occupational injuries, illnesses, and respiratory illnesses (private industry, 2018–2022) (Thousand) 110
Table 14. US Pharmaceutical Market, by Product – Revenue and Forecast to 2030 (US$ Billion) 118
Table 15. US Pharmaceuticals Market For Product, by Type – Revenue and Forecast to 2030 (US$ Billion) 118
Table 16. Top Drugs by Price Increase, January and July 2022. 120
Table 17. Top Drugs by Percentage Price Increase, January and July 2022. 121
Table 18. Global Demand of Pharmaceutical (US$ Billion) 123
Table 19. Global Production of Pharmaceutical (US$ Billion) 123
Table 20. Production Size in US (US$ Billion) 123
Table 21. Novel Drug Approvals for 2023. 133
Table 22. Recent Generic Small Molecules Approvals by US FDA. 137
Table 23. Recent Biological and Biosimilar Products Approvals by US FDA. 141
Table 24. Recent Vaccines Approvals by US FDA. 145
Table 25. Recent Inorganic Growth Strategies in the Pharmaceutical Market 149
Table 26. Recent Organic Growth Strategies in the Pharmaceutical Market 151
LIST OF FIGURES
Figure 1. Pharmaceutical Market Overview.. 17
Figure 2. Small Molecules Segment Held Largest Share of Product Segment in Pharmaceutical Market 17
Figure 3. Pharmaceutical Market – Industry Landscape. 19
Figure 4. Experts’ Opinion. 28
Figure 5. List of supplying markets for pharmaceutical product imported by United States. 37
Figure 6. List of supplying markets for pharmaceutical product imported by United States in US$ Thousand. 38
Figure 7. List of importing markets for a product exported by United States. 40
Figure 8. List of importing markets for a product exported by United States. 41
Figure 9. List of importing markets for a product exported by United States. 42
Figure 10. List of supplying markets for a product imported by Italy. 50
Figure 11. List of supplying markets for a product imported by Italy. 50
Figure 12. List of importing markets for a product exported by Italy. 51
Figure 13. List of importing markets for a product exported by Italy. 52
Figure 14. List of importing markets for a product exported by Italy. 53
Figure 15. Key Trends Impact 108
Figure 16. Key Trends Impact 109
Figure 17. Pharmaceutical Market Impact Analysis of Driver and Restraints. 116
Figure 18. US Pharmaceutical Market – Revenue Forecast and Analysis – 2020–2030. 117
Figure 19. US Branded Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 135
Figure 20. US Generic Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 139
Figure 21. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 143
Figure 22. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 147
Figure 23. Growth Strategies in the Pharmaceutical Market 148
The List of Companies – US Pharmaceutical Market
o Moderna Inc
o AbbVie Inc
o Gilead Sciences Inc
o Regeneron Pharmaceuticals Inc
o Merck & Co Inc
o Abbott Laboratories
o Bristol-Myers Squibb Co
o Vertex Pharmaceuticals Inc
o Pfizer Inc
o Eli Lilly and Co
o Bayer AG
o Johnson & Johnson
o Amgen Inc
o Takeda Pharmaceutical Co Ltd
o Zoetis Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.